Results 101 to 110 of about 10,413 (156)
Some of the next articles are maybe not open access.
Trends in Pharmacological Sciences, 2018
Radiotherapy (RT) is a mainstay treatment for many types of cancer, although it is still a large challenge to enhance radiation damage to tumor tissue and reduce side effects to healthy tissue. Radiosensitizers are promising agents that enhance injury to tumor tissue by accelerating DNA damage and producing free radicals.
Hao, Wang +3 more
openaire +2 more sources
Radiotherapy (RT) is a mainstay treatment for many types of cancer, although it is still a large challenge to enhance radiation damage to tumor tissue and reduce side effects to healthy tissue. Radiosensitizers are promising agents that enhance injury to tumor tissue by accelerating DNA damage and producing free radicals.
Hao, Wang +3 more
openaire +2 more sources
Antimetabolite Radiosensitizers
Journal of Clinical Oncology, 2007Radiosensitization with antimetabolites has improved clinical outcome for patients with solid malignancies, especially cancers of the GI tract, cervix, and head and neck. Fluorouracil (FU) and hydroxyurea have been widely used clinically during the last four decades, and promising results have been observed more recently with gemcitabine. Although the
Donna S, Shewach, Theodore S, Lawrence
openaire +2 more sources
The British Journal of Radiology, 1979
Hendry and Sutton (1978) express concern about the possible sensitizing effect of misonidazole in normal tissues in patients treated with this drug combined with radiotherapy. Their argument is based upon the enhanced effect seen in human normal tissues following treatment in hyperbaric oxygen and upon observations in animals when radiotherapy is ...
G E, Adams, S, Dische
openaire +2 more sources
Hendry and Sutton (1978) express concern about the possible sensitizing effect of misonidazole in normal tissues in patients treated with this drug combined with radiotherapy. Their argument is based upon the enhanced effect seen in human normal tissues following treatment in hyperbaric oxygen and upon observations in animals when radiotherapy is ...
G E, Adams, S, Dische
openaire +2 more sources
The British Journal of Radiology, 1980
I should like to comment on the correspondence between Adams and Dische and Hendry and Sutton in The British Journal of Radiology (1979). These authors were debating the risk of sensitization of normal tissues by misonidazole at the dose levels of radiation and drug that are likely to be used clinically.
openaire +4 more sources
I should like to comment on the correspondence between Adams and Dische and Hendry and Sutton in The British Journal of Radiology (1979). These authors were debating the risk of sensitization of normal tissues by misonidazole at the dose levels of radiation and drug that are likely to be used clinically.
openaire +4 more sources
Biophysical radiosensitization
Radiation and Environmental Biophysics, 1983Experimental studies on normal and tumor-bearing rats revealed that chronic treatment with hydroquinone (5 mg/kg/day) inhibited catalase activity in liver, spleen, blood, and H 18R tumor. 3H-hydroquinone (1.5 microCi/g body weight) showed tumor specificity, with maximum radioactivity in the tumor at 1 h after administration. The biological half-time of
C, Vladescu, M, Apetroae
openaire +2 more sources
Anti-Cancer Drugs, 2014
In parallel with the discovery of the taxanes, our understanding of the molecular underpinnings that comprise the classic biologic principles of fractionated radiotherapy has rapidly evolved over the past half century. Early studies have implicated DNA as the primary target for radiation-induced lethality.
Encouse B, Golden +2 more
openaire +2 more sources
In parallel with the discovery of the taxanes, our understanding of the molecular underpinnings that comprise the classic biologic principles of fractionated radiotherapy has rapidly evolved over the past half century. Early studies have implicated DNA as the primary target for radiation-induced lethality.
Encouse B, Golden +2 more
openaire +2 more sources
Parameters of Radiosensitivity
Radiation Research, 1986Dr. B. Fertil, Dr. E. P. Malaise, and co-workers have shown (1-5) that despite wide variability in the shapes of published in vitro survival curves for cells of human origin, there are, on average, systematic differences in the shapes of survival curves in the low-dose region among cells of distinct histological types.
openaire +2 more sources
The British Journal of Radiology, 1978
In current radiotherapy trials with the oxygen-mimetic radiosensitizing drugs, which are expected to overcome the potential problem of resistant hypoxic tumour cells, no allowance is being made for sensitization of normal tissue. These new agents are competing with hyperbaric oxygen (HBO) for providing therapeutic benefit, and sensitization by HBO was ...
J H, Hendry, M L, Sutton
openaire +2 more sources
In current radiotherapy trials with the oxygen-mimetic radiosensitizing drugs, which are expected to overcome the potential problem of resistant hypoxic tumour cells, no allowance is being made for sensitization of normal tissue. These new agents are competing with hyperbaric oxygen (HBO) for providing therapeutic benefit, and sensitization by HBO was ...
J H, Hendry, M L, Sutton
openaire +2 more sources
Radioprotection by Radiosensitizers
1977The title to this paper was chosen to point deliberately upon the semantic problem involved in characterizing modifications of the response to radiation. In considering the multitarget single-hit model, cellular sensitivity can be modified in the sense of a change in the energy per lethal event and/or in the sense of a change in the amount of ...
L, Révész, B, Littbrand
openaire +2 more sources
[Radiosensitization by hypoxic cell radiosensitizer--present status of radiosensitizer].
Gan no rinsho. Japan journal of cancer clinics, 1991Because of the unsuccessful clinical trials of misonidazole (MISO), many efforts have been made to find a new hypoxic cell sensitizer which is more effective and/or less toxic than MISO. In Japan, RK-28 is already under going Phase II clinical evaluation and RP-170, KU-2285 and KIH-802 have been proven to be effective both in vitro and in vivo and are ...
C, Murayama, T, Mori
openaire +1 more source